Details of the Drug Combination

General Information of Drug Combination (ID: DC0JWR7)

• Drug Combination Name: Simvastatin + Fenofibrate
• Indication: Dyslipidemia; Status: Phase 1 [1]
• Component Drugs:
  Simvastatin (DM30SGU): Small molecular drug
  Fenofibrate (DMFKXDY): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Simvastatin

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[2]
Atherosclerosis	BD40	Approved	[2]
Coronary heart disease	BA80.Z	Approved	[2]
Cystic fibrosis	CA25	Approved	[2]
Depression	6A70-6A7Z	Approved	[2]
Hypercholesterolaemia	5C80.0	Approved	[3]
Hyperlipidemia	5C80.Z	Approved	[2]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[2]
Hypertriglyceridemia	5C80.1	Approved	[2]
Pneumonia	CA40	Approved	[2]
Primary hypercholesterolemia	5C80.00	Approved	[2]
Prostate carcinoma	N.A.	Approved	[2]
Rhinitis	FA20	Approved	[2]
Type-1/2 diabetes	5A10-5A11	Approved	[2]
Stroke	8B20	Investigative	[2]

Simvastatin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[9]

Simvastatin Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[12]

Simvastatin Interacts with 8 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[13]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[15]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[16]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[17]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[14]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Metabolism	[14]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Metabolism	[14]

Simvastatin Interacts with 264 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Activity	[18]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[19]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Affects Response To Substance	[20]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Increases Response To Substance	[21]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Transport	[22]
Stromelysin-1 (MMP3)	OTGBI74Z	MMP3_HUMAN	Increases ADR	[23]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Increases Response To Substance	[24]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Decreases Response To Substance	[25]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Decreases Activity	[22]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[26]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Increases Expression	[26]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Activity	[26]
Prostaglandin E synthase (PTGES)	OTB7YQFU	PTGES_HUMAN	Decreases Expression	[27]
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Decreases Expression	[27]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Decreases Activity	[27]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[27]
Advanced glycosylation end product-specific receptor (AGER)	OTPY0IH7	RAGE_HUMAN	Decreases Expression	[27]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Decreases Expression	[6]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Decreases Expression	[6]
Cell division control protein 45 homolog (CDC45)	OT6NNLOD	CDC45_HUMAN	Decreases Expression	[6]
Integrin beta-like protein 1 (ITGBL1)	OTJDHE17	ITGBL_HUMAN	Decreases Expression	[6]
Protein S100-A8 (S100A8)	OTVMOB3F	S10A8_HUMAN	Increases Expression	[6]
Integrin beta-1 (ITGB1)	OT6G1IAR	ITB1_HUMAN	Decreases Expression	[6]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Expression	[6]
Protein S100-A9 (S100A9)	OTOARHCS	S10A9_HUMAN	Increases Expression	[6]
Protein S100-A6 (S100A6)	OTHHPZQ8	S10A6_HUMAN	Increases Expression	[6]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Decreases Expression	[6]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Increases Expression	[6]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[6]
Annexin A3 (ANXA3)	OTDD8OI7	ANXA3_HUMAN	Decreases Expression	[6]
Keratin, type I cytoskeletal 13 (KRT13)	OTTYSKGX	K1C13_HUMAN	Increases Expression	[6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2)	OTGVC9MY	PLCG2_HUMAN	Increases Expression	[6]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[6]
Keratin, type I cytoskeletal 15 (KRT15)	OTS6WLF7	K1C15_HUMAN	Increases Expression	[6]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[6]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[6]
Insulin-like growth factor-binding protein 6 (IGFBP6)	OTW878VI	IBP6_HUMAN	Increases Expression	[6]
Calmodulin-like protein 3 (CALML3)	OTM8DNQU	CALL3_HUMAN	Increases Expression	[6]
Gap junction beta-2 protein (GJB2)	OTBKLEYB	CXB2_HUMAN	Increases Expression	[6]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Decreases Expression	[6]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Increases Expression	[6]
DNA replication licensing factor MCM4 (MCM4)	OT19PNNG	MCM4_HUMAN	Decreases Expression	[6]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[6]
Macrophage metalloelastase (MMP12)	OT9Z7LHM	MMP12_HUMAN	Increases Expression	[6]
Replication factor C subunit 5 (RFC5)	OTAD79RT	RFC5_HUMAN	Decreases Expression	[6]
Regulator of G-protein signaling 2 (RGS2)	OT0FSRW7	RGS2_HUMAN	Increases Expression	[6]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Increases Expression	[6]
DNA primase small subunit (PRIM1)	OTWWP8Y6	PRI1_HUMAN	Decreases Expression	[6]
Cyclin-dependent kinase inhibitor 1C (CDKN1C)	OTASTJ3Q	CDN1C_HUMAN	Increases Expression	[6]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Decreases Expression	[6]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Increases Expression	[6]
Keratin, type I cytoskeletal 17 (KRT17)	OT6Y1DPK	K1C17_HUMAN	Increases Expression	[6]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Increases Expression	[6]
Focal adhesion kinase 1 (PTK2)	OT3Q1JDY	FAK1_HUMAN	Decreases Activity	[6]
Lymphotoxin-beta (LTB)	OTUFS8CF	TNFC_HUMAN	Decreases Expression	[6]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Increases Expression	[6]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Decreases Expression	[6]
Centromere protein R (ITGB3BP)	OT6Q7GR3	CENPR_HUMAN	Decreases Expression	[6]
Rho GTPase-activating protein 29 (ARHGAP29)	OT8JH4TY	RHG29_HUMAN	Decreases Expression	[6]
Interleukin-20 receptor subunit beta (IL20RB)	OTHFXK95	I20RB_HUMAN	Increases Expression	[6]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[6]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Increases Expression	[6]
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1)	OTYRXD2T	PMYT1_HUMAN	Decreases Expression	[6]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Decreases Expression	[6]
Spondin-2 (SPON2)	OTE7JLNM	SPON2_HUMAN	Increases Expression	[6]
Rac GTPase-activating protein 1 (RACGAP1)	OTQE8IEH	RGAP1_HUMAN	Decreases Expression	[6]
DNA replication factor Cdt1 (CDT1)	OTVY53VG	CDT1_HUMAN	Decreases Expression	[6]
Matrix metalloproteinase-28 (MMP28)	OTHQZXM1	MMP28_HUMAN	Increases Expression	[6]
Alpha-catulin (CTNNAL1)	OTESJ6JD	CTNL1_HUMAN	Decreases Expression	[6]
Protein DBF4 homolog A (DBF4)	OTBL7JHQ	DBF4A_HUMAN	Decreases Expression	[6]
Krueppel-like factor 2 (KLF2)	OTIP1UFX	KLF2_HUMAN	Increases Expression	[6]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Activity	[28]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Localization	[29]
NPC1-like intracellular cholesterol transporter 1 (NPC1L1)	OT6GWW1P	NPCL1_HUMAN	Decreases Expression	[30]
Signal transducer CD24 (CD24)	OT7CODJ4	CD24_HUMAN	Increases Expression	[31]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Decreases Expression	[31]
Killer cell immunoglobulin-like receptor 2DS2 (KIR2DS2)	OTX31RLZ	KI2S2_HUMAN	Decreases Expression	[31]
Killer cell lectin-like receptor subfamily F member 1 (KLRF1)	OTGHZ7FU	KLRF1_HUMAN	Decreases Expression	[31]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)	OTLF4ZB1	IKKA_HUMAN	Increases Phosphorylation	[32]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Nitrosation	[32]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Phosphorylation	[32]
Methylenetetrahydrofolate reductase (MTHFR)	OTUBJSR7	MTHR_HUMAN	Increases Expression	[33]
Sphingosine 1-phosphate receptor 1 (S1PR1)	OTLTXDQT	S1PR1_HUMAN	Increases Expression	[34]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[35]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[36]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Decreases Secretion	[37]
Delta(24)-sterol reductase (DHCR24)	OTP301JW	DHC24_HUMAN	Increases Expression	[38]
Farnesyl pyrophosphate synthase (FDPS)	OT6CKWV5	FPPS_HUMAN	Increases Expression	[39]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Increases Expression	[39]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[40]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Expression	[40]
Toll-like receptor 4 (TLR4)	OTP7ML3S	TLR4_HUMAN	Increases Expression	[41]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B)	OTQ4W7MT	TR11B_HUMAN	Increases Expression	[42]
Dynamin-1-like protein (DNM1L)	OTXK1Q1G	DNM1L_HUMAN	Increases Expression	[43]
Suppressor of cytokine signaling 7 (SOCS7)	OT503VJG	SOCS7_HUMAN	Increases Expression	[44]
Suppressor of cytokine signaling 3 (SOCS3)	OTY183WJ	SOCS3_HUMAN	Increases Expression	[44]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Decreases Expression	[45]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[46]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Increases Expression	[47]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[48]
Serine protease HTRA2, mitochondrial (HTRA2)	OTC7616F	HTRA2_HUMAN	Affects Localization	[43]
Alpha-actinin-4 (ACTN4)	OTCNZAJ5	ACTN4_HUMAN	Increases Expression	[49]
E3 ubiquitin-protein ligase MARCHF6 (MARCHF6)	OTBTA03N	MARH6_HUMAN	Increases Degradation	[50]
Nephrin (NPHS1)	OT21JD3P	NPHN_HUMAN	Increases Expression	[49]
Toll-like receptor 2 (TLR2)	OTGO5P4R	TLR2_HUMAN	Increases Expression	[41]
Apolipoprotein M (APOM)	OTI3FQQC	APOM_HUMAN	Decreases Expression	[51]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Decreases Expression	[52]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Decreases Activity	[53]
Tissue-type plasminogen activator (PLAT)	OTQPDNAB	TPA_HUMAN	Increases Expression	[54]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Decreases Expression	[55]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Decreases Expression	[56]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Prenylation	[57]
Platelet-derived growth factor subunit B (PDGFB)	OTMFMFC3	PDGFB_HUMAN	Decreases Activity	[58]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Increases Expression	[59]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Activity	[60]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Increases Expression	[44]
Interleukin-2 receptor subunit alpha (IL2RA)	OT0MWCHG	IL2RA_HUMAN	Decreases Expression	[44]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Affects Expression	[61]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Decreases Expression	[62]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Increases Expression	[63]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Increases Expression	[64]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[65]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Increases Expression	[66]
Transferrin receptor protein 1 (TFRC)	OT8ZPBDL	TFR1_HUMAN	Affects Expression	[41]
Osteocalcin (BGLAP)	OTK1YLWQ	OSTCN_HUMAN	Increases Expression	[67]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Decreases Secretion	[68]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Activity	[69]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Expression	[70]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[71]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[72]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Decreases Activity	[73]
Integrin beta-2 (ITGB2)	OTEKPEPR	ITB2_HUMAN	Decreases Expression	[74]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Increases Expression	[44]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Decreases Expression	[75]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Affects Expression	[76]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[77]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Decreases Expression	[78]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[74]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Decreases Localization	[79]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[80]
Thrombomodulin (THBD)	OT8VHLKY	TRBM_HUMAN	Increases Expression	[53]
Calpain-1 catalytic subunit (CAPN1)	OTK6OQZR	CAN1_HUMAN	Increases Expression	[81]
Heat shock protein HSP 90-alpha (HSP90AA1)	OTLG1WPK	HS90A_HUMAN	Increases Expression	[82]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Decreases Expression	[83]
Rho-related GTP-binding protein RhoC (RHOC)	OTOLE1FT	RHOC_HUMAN	Increases Expression	[53]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Decreases Activity	[84]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Increases Expression	[85]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[86]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[43]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[77]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[87]
Osteopontin (SPP1)	OTJGC23Y	OSTP_HUMAN	Decreases Expression	[88]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Affects Expression	[89]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Increases Expression	[81]
Cholesteryl ester transfer protein (CETP)	OTAGPPOE	CETP_HUMAN	Decreases Expression	[90]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[91]
Bone morphogenetic protein 2 (BMP2)	OT23T37S	BMP2_HUMAN	Increases Expression	[92]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[77]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Decreases Expression	[93]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Decreases Expression	[94]
HLA class I histocompatibility antigen, alpha chain E (HLA-E)	OTX1CTFB	HLAE_HUMAN	Affects Expression	[61]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Activity	[95]
Indoleamine 2,3-dioxygenase 1 (IDO1)	OT91DBN7	I23O1_HUMAN	Increases Expression	[96]
Ras-related C3 botulinum toxin substrate 2 (RAC2)	OTAOHFNH	RAC2_HUMAN	Affects Localization	[43]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Decreases Expression	[71]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Phosphorylation	[97]
Integrin beta-4 (ITGB4)	OT28UK84	ITB4_HUMAN	Increases Expression	[53]
Cytotoxic T-lymphocyte protein 4 (CTLA4)	OTYQR611	CTLA4_HUMAN	Decreases Expression	[44]
E-selectin (SELE)	OT33RZWY	LYAM2_HUMAN	Decreases Expression	[98]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP)	OT0DH40W	AL5AP_HUMAN	Increases Expression	[63]
Integrin alpha-L (ITGAL)	OTCUQAIS	ITAL_HUMAN	Decreases Expression	[74]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Expression	[96]
Tumor necrosis factor ligand superfamily member 4 (TNFSF4)	OTOCBX7P	TNFL4_HUMAN	Decreases Expression	[99]
Interleukin-4 receptor subunit alpha (IL4R)	OTTXOTCW	IL4RA_HUMAN	Decreases Expression	[44]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[91]
Tumor necrosis factor receptor superfamily member 5 (CD40)	OT5YU2XB	TNR5_HUMAN	Decreases Expression	[41]
CD27 antigen (CD27)	OTH7NA58	CD27_HUMAN	Decreases Expression	[44]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Increases Expression	[100]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[69]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[69]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Increases Expression	[101]
M-phase inducer phosphatase 2 (CDC25B)	OT12MSRY	MPIP2_HUMAN	Affects Expression	[102]
HLA class I histocompatibility antigen, alpha chain F (HLA-F)	OT76CM19	HLAF_HUMAN	Affects Expression	[61]
Type-1 angiotensin II receptor (AGTR1)	OT2NRMJP	AGTR1_HUMAN	Decreases Expression	[103]
Sodium-dependent serotonin transporter (SLC6A4)	OT6FGDLW	SC6A4_HUMAN	Increases Activity	[104]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[105]
Heat shock 70 kDa protein 4 (HSPA4)	OT5HR0AR	HSP74_HUMAN	Increases Expression	[82]
Nitric oxide synthase, inducible (NOS2)	OTKKIOJ1	NOS2_HUMAN	Increases Expression	[106]
Myosin-10 (MYH10)	OTXN2WXS	MYH10_HUMAN	Decreases Expression	[56]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Activity	[107]
C-C chemokine receptor type 2 (CCR2)	OTQ7T10J	CCR2_HUMAN	Decreases Expression	[108]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Decreases Expression	[41]
Signal transducer and activator of transcription 1-alpha/beta (STAT1)	OTLMBUZ6	STAT1_HUMAN	Decreases Expression	[109]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[110]
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4)	OTDK74C0	TNR4_HUMAN	Decreases Expression	[99]
ATP-binding cassette sub-family G member 1 (ABCG1)	OT5BG6MK	ABCG1_HUMAN	Decreases Expression	[52]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[111]
CX3C chemokine receptor 1 (CX3CR1)	OTIM9XT8	CX3C1_HUMAN	Decreases Expression	[112]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[113]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Expression	[89]
Nuclear receptor ROR-gamma (RORC)	OTUBFRPC	RORG_HUMAN	Decreases Expression	[44]
C-C chemokine receptor type 5 (CCR5)	OTP5FMZ4	CCR5_HUMAN	Decreases Expression	[93]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[114]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Decreases Activity	[115]
Cyclin-dependent kinase 4 inhibitor D (CDKN2D)	OT2TTZPZ	CDN2D_HUMAN	Increases Expression	[91]
Ras-related C3 botulinum toxin substrate 3 (RAC3)	OT2RE7A7	RAC3_HUMAN	Affects Localization	[43]
Transforming protein RhoA (RHOA)	OT6YOJ9N	RHOA_HUMAN	Increases Expression	[53]
Ras-related protein Rap-1A (RAP1A)	OT5RH6TI	RAP1A_HUMAN	Decreases Expression	[116]
Ras-related C3 botulinum toxin substrate 1 (RAC1)	OTKRO61U	RAC1_HUMAN	Decreases Activity	[69]
Rho GTPase-activating protein 4 (ARHGAP4)	OTXV053R	RHG04_HUMAN	Increases Expression	[53]
Cyclin-dependent kinase 5 (CDK5)	OT1YAK9F	CDK5_HUMAN	Increases Expression	[89]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Affects Localization	[82]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Phosphorylation	[117]
CD83 antigen (CD83)	OT1V4WQF	CD83_HUMAN	Decreases Expression	[41]
Myosin light chain 5 (MYL5)	OT7CQ24K	MYL5_HUMAN	Increases Expression	[63]
Caldesmon (CALD1)	OTNJKJ6Q	CALD1_HUMAN	Decreases Expression	[53]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[87]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[48]
Sterol regulatory element-binding protein 2 (SREBF2)	OTBXUNPL	SRBP2_HUMAN	Increases Expression	[118]
Forkhead box protein O1 (FOXO1)	OTPJRB6D	FOXO1_HUMAN	Decreases Localization	[115]
TNF receptor-associated factor 2 (TRAF2)	OT1MEZZN	TRAF2_HUMAN	Decreases Expression	[45]
Nuclear factor of activated T-cells, cytoplasmic 3 (NFATC3)	OTYOORME	NFAC3_HUMAN	Decreases Localization	[119]
Myosin-binding protein H (MYBPH)	OTQJBPUR	MYBPH_HUMAN	Increases Expression	[63]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[48]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Increases Expression	[43]
Bone morphogenetic protein receptor type-2 (BMPR2)	OTM9W547	BMPR2_HUMAN	Increases Stability	[120]
Runt-related transcription factor 2 (RUNX2)	OT97RQQM	RUNX2_HUMAN	Increases Expression	[85]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Affects Localization	[53]
Squalene monooxygenase (SQLE)	OT0GGRDO	ERG1_HUMAN	Decreases Degradation	[50]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[121]
Interferon regulatory factor 4 (IRF4)	OT1DHQ1P	IRF4_HUMAN	Decreases Expression	[122]
Tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD)	OTBOSJHO	TRADD_HUMAN	Decreases Expression	[45]
Interleukin-17A (IL17A)	OTY72FT2	IL17_HUMAN	Decreases Expression	[44]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Increases Expression	[7]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[72]
Interleukin-27 subunit alpha (IL27)	OTIS3OF8	IL27A_HUMAN	Increases Expression	[44]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[123]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Decreases Phosphorylation	[115]
Rho guanine nucleotide exchange factor 2 (ARHGEF2)	OTBQTFRT	ARHG2_HUMAN	Increases Expression	[53]
Interleukin-17F (IL17F)	OT9W9DE0	IL17F_HUMAN	Decreases Secretion	[122]
Sphingosine 1-phosphate receptor 3 (S1PR3)	OTXBIYO8	S1PR3_HUMAN	Decreases Expression	[123]
Mitogen-activated protein kinase kinase kinase 14 (MAP3K14)	OTT3DOOL	M3K14_HUMAN	Decreases Expression	[45]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Decreases Expression	[47]
Forkhead box protein P3 (FOXP3)	OTA9Z9OC	FOXP3_HUMAN	Increases Expression	[96]
Interleukin-22 (IL22)	OTW31FU9	IL22_HUMAN	Decreases Secretion	[122]
Interleukin-21 (IL21)	OTABCY4W	IL21_HUMAN	Decreases Expression	[44]
Podocin (NPHS2)	OTLCNUII	PODO_HUMAN	Increases Expression	[49]
Interleukin-23 subunit alpha (IL23A)	OTYO99HC	IL23A_HUMAN	Decreases Expression	[44]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Affects Localization	[43]
Dentin sialophosphoprotein (DSPP)	OT1TYNDN	DSPP_HUMAN	Increases Expression	[124]
7-dehydrocholesterol reductase (DHCR7)	OTLILBUI	DHCR7_HUMAN	Affects Expression	[76]
CD2-associated protein (CD2AP)	OTC76KQM	CD2AP_HUMAN	Increases Expression	[49]
Cytochrome b-245 light chain (CYBA)	OT16N9ZO	CY24A_HUMAN	Affects Response To Substance	[125]
5-hydroxytryptamine receptor 7 (HTR7)	OT44DEWB	5HT7R_HUMAN	Increases Response To Substance	[126]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Response To Substance	[37]
Leptin receptor (LEPR)	OT9H7G0C	LEPR_HUMAN	Affects Response To Substance	[127]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Increases ADR	[23]
Small ribosomal subunit protein mS31 (MRPS31)	OTB0OBWK	RT31_HUMAN	Decreases Response To Substance	[128]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Decreases Response To Substance	[128]
Sterol regulatory element-binding protein cleavage-activating protein (SCAP)	OTCVXOD6	SCAP_HUMAN	Affects Response To Substance	[129]
Kinesin-like protein KIF6 (KIF6)	OTDH3MR4	KIF6_HUMAN	Increases ADR	[130]
Collagen alpha-1(XIII) chain (COL13A1)	OTM9IM6J	CODA1_HUMAN	Decreases Response To Substance	[128]
5-hydroxytryptamine receptor 3B (HTR3B)	OTMGIYRE	5HT3B_HUMAN	Increases Response To Substance	[126]
ELL-associated factor 2 (EAF2)	OTSOET5L	EAF2_HUMAN	Decreases Response To Substance	[128]

Indication(s) of Fenofibrate

Disease Entry	ICD 11	Status	REF
Coronary atherosclerosis	N.A.	Approved	[4]
High cholesterol level	5C80.0	Approved	[5]
Hypercholesterolaemia	5C80.0	Approved	[4]
Hyperlipidemia	5C80.Z	Approved	[4]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[4]
Hypertriglyceridemia	5C80.1	Approved	[4]
Obesity	5B81	Approved	[4]

Fenofibrate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Peroxisome proliferator-activated receptor alpha (PPARA)	TTJ584C	PPARA_HUMAN	Agonist	[135]

Fenofibrate Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[136]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Metabolism	[137]

Fenofibrate Interacts with 240 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[138]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Increases Expression	[138]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[139]
S-adenosylmethionine synthase isoform type-2 (MAT2A)	OTFJMIQR	METK2_HUMAN	Decreases Expression	[139]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2)	OTJ8LX4N	PCKGM_HUMAN	Increases Expression	[139]
Acyl-CoA (FADS1)	OTUYOYHX	FADS1_HUMAN	Increases Expression	[29]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Decreases Activity	[140]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Increases Expression	[141]
Cytochrome P450 3A7 (CYP3A7)	OTTCDHHM	CP3A7_HUMAN	Increases Expression	[141]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Increases Activity	[142]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[36]
Isocitrate dehydrogenase subunit beta, mitochondrial (IDH3B)	OTR89YF5	IDH3B_HUMAN	Increases Expression	[132]
Apolipoprotein C-III (APOC3)	OTW3520C	APOC3_HUMAN	Decreases Expression	[132]
Lipoprotein lipase (LPL)	OTTW0267	LIPL_HUMAN	Increases Expression	[132]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Increases Expression	[132]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1)	OTVKRET0	THIK_HUMAN	Increases Expression	[132]
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM)	OTA4P0FC	ACADM_HUMAN	Increases Expression	[132]
Succinate dehydrogenase iron-sulfur subunit, mitochondrial (SDHB)	OTRE1M1T	SDHB_HUMAN	Increases Expression	[132]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Increases Expression	[132]
Enoyl-CoA hydratase, mitochondrial (ECHS1)	OTS0593S	ECHM_HUMAN	Increases Expression	[132]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1)	OTB06ESI	ACSL1_HUMAN	Increases Expression	[132]
Phosphoglucomutase-1 (PGM1)	OT3VM4JX	PGM1_HUMAN	Increases Expression	[132]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL)	OT50L4XB	ACADV_HUMAN	Increases Expression	[132]
Succinate--CoA ligase subunit alpha, mitochondrial (SUCLG1)	OTDCSPXH	SUCA_HUMAN	Increases Expression	[132]
Trifunctional enzyme subunit beta, mitochondrial (HADHB)	OT4Y1I62	ECHB_HUMAN	Increases Expression	[132]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1)	OT8LCZCT	MMSA_HUMAN	Increases Expression	[132]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Decreases Expression	[132]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1)	OTM0A0DY	ACOX1_HUMAN	Increases Expression	[132]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH)	OTJDOL20	HCDH_HUMAN	Increases Expression	[132]
Long-chain fatty acid transport protein 4 (SLC27A4)	OTWT4HAF	S27A4_HUMAN	Increases Expression	[132]
Aconitate hydratase, mitochondrial (ACO2)	OTF2UVNV	ACON_HUMAN	Increases Expression	[132]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B)	OTQ4W7MT	TR11B_HUMAN	Decreases Expression	[133]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Decreases Expression	[133]
Krueppel-like factor 11 (KLF11)	OTKVQDJD	KLF11_HUMAN	Increases Expression	[133]
Long-chain fatty acid transport protein 2 (SLC27A2)	OT7JEG5F	S27A2_HUMAN	Increases Expression	[133]
Transcription intermediary factor 1-alpha (TRIM24)	OTA45FTS	TIF1A_HUMAN	Increases Expression	[133]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Decreases Expression	[133]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2)	OT6Y1QZN	IRAK2_HUMAN	Increases Expression	[133]
Proline dehydrogenase 1, mitochondrial (PRODH)	OT7SQ1C7	PROD_HUMAN	Decreases Expression	[133]
Aquaporin-9 (AQP9)	OTLGH5ZY	AQP9_HUMAN	Decreases Expression	[133]
LYR motif-containing protein 1 (LYRM1)	OTV3AJDJ	LYRM1_HUMAN	Increases Expression	[133]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20)	OT6CLFXB	MCAT_HUMAN	Increases Expression	[133]
Perilipin-1 (PLIN1)	OT3OAAZ4	PLIN1_HUMAN	Increases Expression	[133]
Peroxisomal membrane protein 11A (PEX11A)	OT8MJ9CJ	PX11A_HUMAN	Increases Expression	[133]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21)	OT3EDGXO	TNR21_HUMAN	Increases Expression	[133]
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (GCAT)	OT6WZPWV	KBL_HUMAN	Decreases Expression	[133]
Alcohol dehydrogenase 1C (ADH1C)	OTO1DV7F	ADH1G_HUMAN	Decreases Expression	[133]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Decreases Expression	[133]
L-lactate dehydrogenase B chain (LDHB)	OT9B1CT3	LDHB_HUMAN	Increases Expression	[133]
Galactose-1-phosphate uridylyltransferase (GALT)	OTCATU66	GALT_HUMAN	Increases Expression	[133]
All-trans-retinol dehydrogenase ADH4 (ADH4)	OTKDKKNG	ADH4_HUMAN	Decreases Expression	[133]
Monocyte differentiation antigen CD14 (CD14)	OT83GJ47	CD14_HUMAN	Increases Expression	[133]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Increases Expression	[133]
Electron transfer flavoprotein subunit alpha, mitochondrial (ETFA)	OTXX61VZ	ETFA_HUMAN	Increases Expression	[133]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Expression	[133]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Increases Expression	[133]
Fumarylacetoacetase (FAH)	OTGZA1YR	FAAA_HUMAN	Increases Expression	[133]
Arylacetamide deacetylase (AADAC)	OT8VACT2	AAAD_HUMAN	Increases Expression	[133]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4)	OTMWFDAC	AT2B4_HUMAN	Increases Expression	[133]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Increases Expression	[133]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Increases Expression	[133]
Pyruvate kinase PKLR (PKLR)	OTTTM1QI	KPYR_HUMAN	Decreases Expression	[133]
Glycerol kinase (GK)	OTK2YRA0	GLPK_HUMAN	Increases Expression	[133]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Increases Expression	[133]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1)	OTNWEJ5Y	PCKGC_HUMAN	Increases Expression	[133]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	OTJ6FM9F	G6PC1_HUMAN	Decreases Expression	[133]
Trifunctional enzyme subunit alpha, mitochondrial (HADHA)	OTO557N2	ECHA_HUMAN	Increases Expression	[133]
3-ketoacyl-CoA thiolase, mitochondrial (ACAA2)	OTGLVWOP	THIM_HUMAN	Increases Expression	[133]
Tryptophan 2,3-dioxygenase (TDO2)	OTV5HKJ4	T23O_HUMAN	Increases Expression	[133]
Flavin-containing monooxygenase 5 (FMO5)	OTTILF8T	FMO5_HUMAN	Decreases Expression	[133]
Peroxisomal multifunctional enzyme type 2 (HSD17B4)	OT8733D7	DHB4_HUMAN	Increases Expression	[133]
Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2)	OTC3RUN9	HMCS2_HUMAN	Increases Expression	[133]
Cytochrome P450 4A11 (CYP4A11)	OTPU5J0S	CP4AB_HUMAN	Increases Expression	[133]
Tyrosine-protein kinase Mer (MERTK)	OTWBRAJ6	MERTK_HUMAN	Increases Expression	[133]
Krueppel-like factor 10 (KLF10)	OT4F4UGS	KLF10_HUMAN	Increases Expression	[133]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2)	OTTUU92F	ENPP2_HUMAN	Decreases Expression	[133]
Glycine N-methyltransferase (GNMT)	OT0O2OQO	GNMT_HUMAN	Decreases Expression	[133]
Metabotropic glutamate receptor 3 (GRM3)	OTJFGE9S	GRM3_HUMAN	Increases Expression	[133]
Hepatic sodium/bile acid cotransporter (SLC10A1)	OTUJVMCL	NTCP_HUMAN	Decreases Expression	[133]
Monocyte to macrophage differentiation factor (MMD)	OTB5I4OC	PAQRB_HUMAN	Increases Expression	[133]
2'-5'-oligoadenylate synthase-like protein (OASL)	OTZ05YRP	OASL_HUMAN	Increases Expression	[133]
Myosin light chain kinase, smooth muscle (MYLK)	OT78QB4A	MYLK_HUMAN	Decreases Expression	[133]
Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (ETFDH)	OTOSKSFH	ETFD_HUMAN	Increases Expression	[133]
Laminin subunit alpha-4 (LAMA4)	OTHI7TA0	LAMA4_HUMAN	Increases Expression	[133]
kinase isozyme 4, mitochondrial (PDK4)	OTCMHMBZ	PDK4_HUMAN	Increases Expression	[133]
Phospholipase A1 member A (PLA1A)	OT2IXYNX	PLA1A_HUMAN	Increases Expression	[133]
Protein LBH (LBH)	OT87AT1X	LBH_HUMAN	Increases Expression	[133]
NEDD4-binding protein 2-like 1 (N4BP2L1)	OTEGV3GO	N42L1_HUMAN	Increases Expression	[133]
Cytochrome P450 4A22 (CYP4A22)	OTHO7KC4	CP4AM_HUMAN	Increases Expression	[133]
Protein FAM222A (FAM222A)	OTRD9AUH	F222A_HUMAN	Increases Expression	[133]
PI-PLC X domain-containing protein 3 (PLCXD3)	OTJNSWMU	PLCX3_HUMAN	Decreases Expression	[133]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3)	OTDMU3GP	CR3L3_HUMAN	Increases Expression	[133]
Lysophospholipid acyltransferase 5 (LPCAT3)	OTWI96P4	MBOA5_HUMAN	Increases Expression	[133]
Solute carrier family 25 member 34 (SLC25A34)	OTY1YFLG	S2534_HUMAN	Increases Expression	[133]
Leucine-rich repeat-containing protein 31 (LRRC31)	OT7VCU13	LRC31_HUMAN	Increases Expression	[133]
Lysophosphatidylcholine acyltransferase 2 (LPCAT2)	OT6NTBAA	PCAT2_HUMAN	Increases Expression	[133]
Monocarboxylate transporter 13 (SLC16A13)	OTAJ5CPB	MOT13_HUMAN	Increases Expression	[133]
Target of Nesh-SH3 (ABI3BP)	OTW8DN50	TARSH_HUMAN	Decreases Expression	[133]
Alpha-protein kinase 2 (ALPK2)	OTWZZDQ9	ALPK2_HUMAN	Increases Expression	[133]
4-hydroxy-2-oxoglutarate aldolase, mitochondrial (HOGA1)	OT7XETW4	HOGA1_HUMAN	Decreases Expression	[133]
Sphingosine-1-phosphate transporter SPNS2 (SPNS2)	OTPODAPU	SPNS2_HUMAN	Increases Expression	[133]
Cyclin-dependent kinase 20 (CDK20)	OTOLNN68	CDK20_HUMAN	Increases Expression	[133]
Cytochrome P450 4X1 (CYP4X1)	OTMTEUNE	CP4X1_HUMAN	Increases Expression	[133]
Uncharacterized protein FAM241A (FAM241A)	OTC12ETA	F241A_HUMAN	Increases Expression	[133]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A)	OTVG1VG0	NLS1_HUMAN	Decreases Expression	[133]
Pantothenate kinase 1 (PANK1)	OT2CZVRT	PANK1_HUMAN	Increases Expression	[133]
Thyroid hormone-inducible hepatic protein (THRSP)	OTKYE01L	THRSP_HUMAN	Decreases Expression	[133]
Interferon regulatory factor 7 (IRF7)	OTC1A2PQ	IRF7_HUMAN	Increases Expression	[133]
Bcl-2-modifying factor (BMF)	OT90NSLI	BMF_HUMAN	Increases Expression	[133]
Membrane-spanning 4-domains subfamily A member 10 (MS4A10)	OTH3LAUX	M4A10_HUMAN	Decreases Expression	[133]
Perilipin-2 (PLIN2)	OTRXJ9UN	PLIN2_HUMAN	Increases Expression	[133]
C-C motif chemokine 13 (CCL13)	OTNX0JD0	CCL13_HUMAN	Increases Expression	[133]
Ion channel TACAN (TMEM120A)	OTBS3YWY	TACAN_HUMAN	Decreases Expression	[133]
Angiopoietin-related protein 4 (ANGPTL4)	OTQL5SPX	ANGL4_HUMAN	Increases Expression	[133]
Alanine--glyoxylate aminotransferase 2, mitochondrial (AGXT2)	OTO6QUTM	AGT2_HUMAN	Decreases Expression	[133]
cAMP-dependent protein kinase inhibitor beta (PKIB)	OT7C8GFN	IPKB_HUMAN	Increases Expression	[133]
Potassium channel subfamily K member 13 (KCNK13)	OTMOT2KX	KCNKD_HUMAN	Increases Expression	[133]
Serine/threonine-protein kinase Sgk2 (SGK2)	OTCTVSHF	SGK2_HUMAN	Increases Expression	[133]
Acetyl-coenzyme A synthetase, cytoplasmic (ACSS2)	OTB1FZJU	ACSA_HUMAN	Decreases Expression	[133]
Protein C19orf12 (C19ORF12)	OTVSJ1AR	CS012_HUMAN	Increases Expression	[133]
Ethanolamine kinase 2 (ETNK2)	OT5S1Z75	EKI2_HUMAN	Decreases Expression	[133]
Phosphatidylethanolamine N-methyltransferase (PEMT)	OTKXRUL9	PEMT_HUMAN	Increases Expression	[133]
SH3 domain-binding glutamic acid-rich-like protein 2 (SH3BGRL2)	OTOX4XT7	SH3L2_HUMAN	Increases Expression	[133]
Excitatory amino acid transporter 5 (SLC1A7)	OTVN5C6W	EAA5_HUMAN	Increases Expression	[134]
Podocalyxin (PODXL)	OTPNQXF3	PODXL_HUMAN	Decreases Expression	[134]
Class E basic helix-loop-helix protein 40 (BHLHE40)	OTITX14U	BHE40_HUMAN	Decreases Expression	[134]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[134]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2)	OT8L6EGI	BCAT2_HUMAN	Increases Expression	[134]
Transcription factor MafG (MAFG)	OTBQFUZH	MAFG_HUMAN	Increases Expression	[134]
D-3-phosphoglycerate dehydrogenase (PHGDH)	OT1LMRTG	SERA_HUMAN	Increases Expression	[134]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1)	OTEAUJXN	TRIA1_HUMAN	Decreases Expression	[134]
NUAK family SNF1-like kinase 1 (NUAK1)	OTLLHJJQ	NUAK1_HUMAN	Decreases Expression	[134]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[134]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1)	OTERJ4VQ	SO2B1_HUMAN	Decreases Expression	[134]
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (GCNT3)	OTQ9ALTR	GCNT3_HUMAN	Increases Expression	[134]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Affects Activity	[134]
Alpha-enolase (ENO1)	OTB1KWJS	ENOA_HUMAN	Increases Expression	[134]
Bifunctional glutamate/proline--tRNA ligase (EPRS1)	OTXK0FLB	SYEP_HUMAN	Increases Expression	[134]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[134]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Increases Expression	[134]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[134]
RNA-binding protein RO60 (RO60)	OTLGM5A8	RO60_HUMAN	Decreases Expression	[134]
Retinoic acid receptor alpha (RARA)	OT192V9V	RARA_HUMAN	Decreases Expression	[134]
Histone H1.2 (H1-2)	OT0AVI4M	H12_HUMAN	Decreases Expression	[134]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[134]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Affects Activity	[134]
Transcription factor E3 (TFE3)	OTM99ZWH	TFE3_HUMAN	Increases Expression	[134]
Retinoic acid receptor RXR-alpha (RXRA)	OTP1TBDM	RXRA_HUMAN	Decreases Expression	[134]
B-cell lymphoma 3 protein (BCL3)	OT1M5B95	BCL3_HUMAN	Decreases Expression	[134]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Decreases Expression	[134]
ETS domain-containing protein Elk-4 (ELK4)	OTVSSEOE	ELK4_HUMAN	Increases Expression	[134]
High affinity cationic amino acid transporter 1 (SLC7A1)	OTR2ZVA8	CTR1_HUMAN	Increases Expression	[134]
Cystathionine gamma-lyase (CTH)	OTC90LA0	CGL_HUMAN	Increases Expression	[134]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[134]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Affects Activity	[134]
Glycine--tRNA ligase (GARS1)	OT5B6R9Y	GARS_HUMAN	Increases Expression	[134]
Isoleucine--tRNA ligase, cytoplasmic (IARS1)	OT9WXH5N	SYIC_HUMAN	Increases Expression	[134]
Eukaryotic translation initiation factor 1 (EIF1)	OTB4GZ0V	EIF1_HUMAN	Increases Expression	[134]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9)	OTHRUON2	SC6A9_HUMAN	Increases Expression	[134]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Increases Expression	[134]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Increases Expression	[134]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1)	OTYHXLWZ	BCAT1_HUMAN	Decreases Expression	[134]
Serine/threonine-protein kinase SIK1 (SIK1)	OT6FCHME	SIK1_HUMAN	Increases Expression	[134]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Increases Expression	[134]
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Increases Expression	[134]
Adenylate cyclase type 1 (ADCY1)	OTSLLFZO	ADCY1_HUMAN	Decreases Expression	[134]
Ras-related protein Rab-31 (RAB31)	OTMLXQZ0	RAB31_HUMAN	Decreases Expression	[134]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Decreases Expression	[134]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3)	OTWMKYD9	HERC3_HUMAN	Increases Expression	[134]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Affects Activity	[134]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Decreases Expression	[134]
Neuronal regeneration-related protein (NREP)	OT2AZPKK	NREP_HUMAN	Decreases Expression	[134]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Affects Activity	[134]
Dual specificity protein phosphatase 5 (DUSP5)	OTH96RA7	DUS5_HUMAN	Increases Expression	[134]
Glycerol-3-phosphate acyltransferase 3 (GPAT3)	OTJUGPK0	GPAT3_HUMAN	Increases Expression	[134]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Decreases Expression	[134]
Extracellular sulfatase Sulf-2 (SULF2)	OTIXMUVL	SULF2_HUMAN	Decreases Expression	[134]
Probable ATP-dependent RNA helicase DHX37 (DHX37)	OTM1A5KP	DHX37_HUMAN	Increases Expression	[134]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1)	OT0HYZIU	S3TC1_HUMAN	Increases Expression	[134]
Sortilin-related receptor (SORL1)	OTQ8FFNS	SORL_HUMAN	Decreases Expression	[134]
KICSTOR complex protein ITFG2 (ITFG2)	OT0NLZ8I	ITFG2_HUMAN	Increases Expression	[134]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1)	OT2363Z9	T53I1_HUMAN	Decreases Expression	[134]
Protein FAM89A (FAM89A)	OTNASAXT	FA89A_HUMAN	Increases Expression	[134]
Spermatid perinuclear RNA-binding protein (STRBP)	OTU7XLZL	STRBP_HUMAN	Increases Expression	[134]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[134]
Protein orai-3 (ORAI3)	OTUP3OH3	ORAI3_HUMAN	Decreases Expression	[134]
Ferroptosis suppressor protein 1 (AIFM2)	OT57XWXO	FSP1_HUMAN	Increases Expression	[134]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Increases Expression	[134]
Ankyrin repeat family A protein 2 (ANKRA2)	OTLSLV5A	ANRA2_HUMAN	Increases Expression	[134]
Gephyrin (GPHN)	OTAKK1SV	GEPH_HUMAN	Increases Expression	[134]
Ectonucleoside triphosphate diphosphohydrolase 7 (ENTPD7)	OT3QER33	ENTP7_HUMAN	Decreases Expression	[134]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Decreases Expression	[134]
Leucine--tRNA ligase, cytoplasmic (LARS1)	OT4557NF	SYLC_HUMAN	Increases Expression	[134]
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2)	OTM3CQZT	BIG2_HUMAN	Increases Expression	[134]
Bifunctional epoxide hydrolase 2 (EPHX2)	OTPTRCNW	HYES_HUMAN	Affects Expression	[143]
Cytochrome P450 2J2 (CYP2J2)	OTJBTEH8	CP2J2_HUMAN	Affects Expression	[143]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Increases Expression	[144]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Expression	[145]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Decreases Expression	[146]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Decreases Expression	[147]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Expression	[148]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[72]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Decreases Expression	[147]
Matrilysin (MMP7)	OTVT3SEJ	MMP7_HUMAN	Decreases Expression	[147]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[149]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Increases Expression	[150]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Expression	[147]
Fatty acid-binding protein, adipocyte (FABP4)	OT3DKFOU	FABP4_HUMAN	Increases Expression	[151]
Polyunsaturated fatty acid lipoxygenase ALOX12 (ALOX12)	OTFL5KR5	LOX12_HUMAN	Increases Expression	[151]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Affects Localization	[147]
Cytochrome P450 7A1 (CYP7A1)	OT8Z5KLD	CP7A1_HUMAN	Decreases Expression	[152]
Tumor necrosis factor receptor superfamily member 5 (CD40)	OT5YU2XB	TNR5_HUMAN	Decreases Expression	[145]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Decreases Expression	[147]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Expression	[153]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Increases Expression	[144]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Decreases Expression	[150]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Decreases Expression	[150]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Increases Expression	[154]
5'-AMP-activated protein kinase subunit gamma-1 (PRKAG1)	OTW00PRY	AAKG1_HUMAN	Increases Expression	[147]
Oxysterols receptor LXR-beta (NR1H2)	OT4APA60	NR1H2_HUMAN	Increases Expression	[144]
Caveolin-1 (CAV1)	OTEZUR1L	CAV1_HUMAN	Increases Expression	[155]
Peroxisome proliferator-activated receptor delta (PPARD)	OTI4WTOP	PPARD_HUMAN	Increases Expression	[144]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[145]
Platelet-activating factor acetylhydrolase (PLA2G7)	OT6H6AMO	PAFA_HUMAN	Decreases Activity	[156]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[144]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Decreases Expression	[145]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Increases Expression	[157]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Increases Expression	[153]
Bcl-2-related protein A1 (BCL2A1)	OTWRYSNA	B2LA1_HUMAN	Decreases Expression	[145]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[72]
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	OTI0DU9Y	PCSK9_HUMAN	Increases Expression	[148]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[158]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	OTAYZMOY	SIR1_HUMAN	Increases Expression	[159]
Tribbles homolog 3 (TRIB3)	OTG5OS7X	TRIB3_HUMAN	Decreases Expression	[160]
Semaphorin-6B (SEMA6B)	OT3VVVUO	SEM6B_HUMAN	Decreases Expression	[161]
Fibroblast growth factor 21 (FGF21)	OT3RXVRD	FGF21_HUMAN	Increases Expression	[162]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Increases Phosphorylation	[147]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	OT7TNF0L	AAPK1_HUMAN	Decreases Response To Substance	[147]
HLA class I histocompatibility antigen, A alpha chain (HLA-A)	OTAH14LU	HLAA_HUMAN	Affects Response To Substance	[163]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Affects Response To Substance	[164]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Hyperlipidaemia	DCDI8VM	N. A.	Phase 1	[165]

References

• [1] ClinicalTrials.gov (NCT00300456) Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
• [2] Simvastatin FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2955).
• [4] Fenofibrate FDA Label
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7186).
• [6] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [7] Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008 Mar;51(3):267-73. doi: 10.1097/FJC.0b013e3181624b44.
• [8] Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
• [9] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
• [10] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [11] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [12] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [13] A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
• [14] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [15] Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
• [16] In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
• [17] Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
• [18] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [19] Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
• [20] Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2007 Jan;47(1):87-93. doi: 10.1177/0091270006295063.
• [21] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [22] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [23] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [24] Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007 Apr;55(4):310-7. doi: 10.1016/j.phrs.2006.12.009. Epub 2007 Jan 14.
• [25] Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
• [26] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [27] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [28] The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
• [29] Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
• [30] Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008 May;198(1):198-207.
• [31] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [32] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [33] Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Cardiovasc Res. 2008 Oct 1;80(1):151-8.
• [34] Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost. 2008 Jul;100(1):119-26.
• [35] High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am J Nephrol. 2009;30(2):99-111.
• [36] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [37] Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
• [38] Simvastatin modulates the Alzheimer's disease-related gene seladin-1. J Alzheimers Dis. 2012;28(2):297-301.
• [39] Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells. J Clin Endocrinol Metab. 2013 Mar;98(3):E455-62.
• [40] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [41] Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
• [42] [Effect of simvastatin on the function of MG63 cell line]. Shanghai Kou Qiang Yi Xue. 2010 Dec;19(6):658-62.
• [43] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [44] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [45] Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol. 2007 Feb 15;178(4):2507-16. doi: 10.4049/jimmunol.178.4.2507.
• [46] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [47] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [48] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [49] Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 2006 Jul;70(1):177-86. doi: 10.1038/sj.ki.5001515. Epub 2006 May 17.
• [50] Cholesterol increases protein levels of the E3 ligase MARCH6 and thereby stimulates protein degradation. J Biol Chem. 2019 Feb 15;294(7):2436-2448. doi: 10.1074/jbc.RA118.005069. Epub 2018 Dec 13.
• [51] Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis. 2011 Jul 5;10:112. doi: 10.1186/1476-511X-10-112.
• [52] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [53] Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004 May;30(5):662-70. doi: 10.1165/rcmb.2003-0267OC. Epub 2003 Nov 20.
• [54] Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int. 2002 Nov;62(5):1611-9. doi: 10.1046/j.1523-1755.2002.00601.x.
• [55] Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008 Jun;26(6):1147-55. doi: 10.1097/HJH.0b013e3282f97dde.
• [56] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [57] Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res. 1994 Jun;85(6):633-8. doi: 10.1111/j.1349-7006.1994.tb02406.x.
• [58] Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int. 1993 Sep;44(3):503-8. doi: 10.1038/ki.1993.274.
• [59] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [60] Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol. 2007 Aug;43(2):168-76. doi: 10.1016/j.yjmcc.2007.05.006. Epub 2007 May 18.
• [61] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [62] Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
• [63] A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One. 2006 Dec 20;1(1):e97. doi: 10.1371/journal.pone.0000097.
• [64] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [65] Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
• [66] Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. J Hepatol. 1999 May;30(5):904-10. doi: 10.1016/s0168-8278(99)80146-9.
• [67] The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005 Jun;20(3):438-44. doi: 10.3346/jkms.2005.20.3.438.
• [68] Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007 May;27(5):1043-9. doi: 10.1161/ATVBAHA.107.139881. Epub 2007 Feb 15.
• [69] Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009 May;21(5):1317-22. doi: 10.3892/or_00000357.
• [70] Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1999 Sep 15;84(6):655-9. doi: 10.1016/s0002-9149(99)00411-7.
• [71] Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
• [72] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [73] Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
• [74] Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):397-403. doi: 10.1161/01.ATV.0000059384.34874.F0. Epub 2003 Jan 30.
• [75] Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
• [76] Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
• [77] Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
• [78] [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;39(1):72-5.
• [79] Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int. 2003 Jun;63(6):2065-74. doi: 10.1046/j.1523-1755.2003.t01-2-00004.x.
• [80] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [81] [Simvastatin-induced apoptosis of K562 cells is mediated by endoplasmic reticulum stress]. Yao Xue Xue Bao. 2008 Apr;43(4):371-7.
• [82] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [83] Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2008 Jul 25;372(2):356-61. doi: 10.1016/j.bbrc.2008.05.043. Epub 2008 May 19.
• [84] Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
• [85] The role of simvastatin in the osteogenesis of injectable tissue-engineered bone based on human adipose-derived stromal cells and platelet-rich plasma. Biomaterials. 2010 Jul;31(20):5325-35. doi: 10.1016/j.biomaterials.2010.03.037. Epub 2010 Apr 9.
• [86] Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010 Sep 11;41(1):118-24. doi: 10.1016/j.ejps.2010.05.021. Epub 2010 Jun 8.
• [87] Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol. 2007 Aug;58 Suppl 3:141-8.
• [88] Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011 Jan;25(1):41-7.
• [89] Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
• [90] Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol. 1999 Summer;6(2):85-90.
• [91] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [92] Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000 May 19;271(3):688-92. doi: 10.1006/bbrc.2000.2697.
• [93] Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Transplant Proc. 2006 Nov;38(9):2899-904. doi: 10.1016/j.transproceed.2006.08.136.
• [94] Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000 May 15;69(9):1830-6. doi: 10.1097/00007890-200005150-00017.
• [95] Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004 Apr;94(4):403-9. doi: 10.1254/jphs.94.403.
• [96] Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol. 2010 Aug;161(2):298-305. doi: 10.1111/j.1365-2249.2010.04170.x. Epub 2010 May 18.
• [97] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [98] Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003 Nov;88(11):5341-7. doi: 10.1210/jc.2003-030724.
• [99] Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction. J Int Med Res. 2009 May-Jun;37(3):601-10. doi: 10.1177/147323000903700302.
• [100] Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2083-9. doi: 10.1161/01.ATV.0000096207.01487.36. Epub 2003 Sep 18.
• [101] Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 Oct 15;172(8):987-93. doi: 10.1164/rccm.200501-041OC. Epub 2005 Jul 7.
• [102] Temporal gene expression analysis of human coronary artery endothelial cells treated with Simvastatin. Gene Expr. 2008;14(4):229-39. doi: 10.3727/105221608786883834.
• [103] Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007 May;49(5):299-305. doi: 10.1097/FJC.0b013e31803d35ce.
• [104] Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
• [105] Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 2008;122(2):191-202. doi: 10.1016/j.thromres.2007.09.017. Epub 2007 Nov 26.
• [106] Mechanism of simvastatin-induced K562 cell apoptosis. Pharmacology. 2009;84(4):191-5. doi: 10.1159/000235907. Epub 2009 Sep 2.
• [107] Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009 Aug;33(2):107-14.
• [108] HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005 Mar 22;111(11):1439-47. doi: 10.1161/01.CIR.0000158484.18024.1F.
• [109] Molecular mechanisms underlying the inhibition of IFN--induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem. 2011 Feb;112(2):675-83. doi: 10.1002/jcb.22976.
• [110] [Effects of simvastatin on proliferation and apoptosis of acute monocytic leukemia cell line SHI-1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):612-6.
• [111] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [112] [Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Mar;28(3):475-7.
• [113] Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
• [114] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [115] Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
• [116] Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. Cancer Res Commun. 2023 Dec 8;3(12):2497-2509. doi: 10.1158/2767-9764.CRC-23-0350.
• [117] HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 2005 Mar;19(3):476-8. doi: 10.1096/fj.04-2745fje. Epub 2004 Dec 29.
• [118] Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010 Apr 15;79(8):1200-9. doi: 10.1016/j.bcp.2009.12.007. Epub 2009 Dec 14.
• [119] Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Mol Neurobiol. 2010 Jun;41(2-3):384-91. doi: 10.1007/s12035-010-8122-8. Epub 2010 Apr 6.
• [120] Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun. 2006 Jan 6;339(1):59-64. doi: 10.1016/j.bbrc.2005.10.187. Epub 2005 Nov 8.
• [121] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [122] Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.
• [123] Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol. 2008 Nov 15;181(10):7332-40. doi: 10.4049/jimmunol.181.10.7332.
• [124] Simvastatin induces the odontogenic differentiation of human dental pulp stem cells in vitro and in vivo. J Endod. 2009 Mar;35(3):367-72. doi: 10.1016/j.joen.2008.11.024.
• [125] A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Clin Chim Acta. 2005 Oct;360(1-2):46-51. doi: 10.1016/j.cccn.2005.04.001.
• [126] Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
• [127] Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men. Diabetes Res Clin Pract. 2003 Dec;62(3):169-75. doi: 10.1016/s0168-8227(03)00163-3.
• [128] NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
• [129] Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J. 2005;5(6):359-64. doi: 10.1038/sj.tpj.6500334.
• [130] Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43. doi: 10.1016/j.jacc.2007.05.057.
• [131] Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
• [132] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [133] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [134] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [135] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [136] Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
• [137] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [138] The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol. 2005 Jun;62(6):526-30.
• [139] In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006 Mar 28;5:13.
• [140] Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21.
• [141] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [142] Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism. 2011 Apr;60(4):513-22.
• [143] Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
• [144] On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009 Aug;205(2):413-9. doi: 10.1016/j.atherosclerosis.2009.01.008. Epub 2009 Jan 19.
• [145] Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia. 2010 Aug;24(8):1476-86. doi: 10.1038/leu.2010.117. Epub 2010 Jun 3.
• [146] Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994 Dec 9;269(49):31012-8.
• [147] AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.
• [148] Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis. 2011 Jul;217(1):165-70. doi: 10.1016/j.atherosclerosis.2011.02.012. Epub 2011 Feb 22.
• [149] Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt. Apoptosis. 2005 Mar;10(2):349-58. doi: 10.1007/s10495-005-0809-3.
• [150] Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells. Environ Toxicol. 2018 Feb;33(2):234-247. doi: 10.1002/tox.22511. Epub 2017 Nov 14.
• [151] Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
• [152] Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004 Feb;59(12):855-61. doi: 10.1007/s00228-003-0704-1. Epub 2003 Dec 18.
• [153] Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006 Feb;29(2):195-201. doi: 10.2337/diacare.29.02.06.dc05-1418.
• [154] Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes. Biochimie. 2007 Mar;89(3):329-36. doi: 10.1016/j.biochi.2006.09.017. Epub 2006 Oct 18.
• [155] Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res. 2004 Nov;45(11):2015-24. doi: 10.1194/jlr.M400049-JLR200. Epub 2004 Aug 16.
• [156] The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007 Aug;193(2):428-37. doi: 10.1016/j.atherosclerosis.2006.07.010. Epub 2006 Sep 5.
• [157] Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology. 2009 Sep;50(3):880-92. doi: 10.1002/hep.23049.
• [158] Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice. FASEB J. 2006 Jul;20(9):1328-35. doi: 10.1096/fj.05-5368com.
• [159] Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells. Environ Toxicol. 2021 Dec;36(12):2551-2561. doi: 10.1002/tox.23369. Epub 2021 Sep 14.
• [160] PML-RAR interaction with TRIB3 impedes PPAR/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020 Aug 15;10(22):10326-10340. doi: 10.7150/thno.45924. eCollection 2020.
• [161] Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol. 2006 Apr;28(4):977-84.
• [162] Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. 2012 Apr;61(4):797-806. doi: 10.2337/db11-0846. Epub 2012 Feb 14.
• [163] Association of Liver Injury From Specific Drugs, or Groups of?Drugs, With Polymorphisms in HLA and Other Genes in a?Genome-Wide Association Study. Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.
• [164] Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood Coagul Fibrinolysis. 2006 Jan;17(1):35-8. doi: 10.1097/01.mbc.0000198052.65505.00.
• [165] ClinicalTrials.gov (NCT01674712) A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease. U.S. National Institutes of Health.